166 related articles for article (PubMed ID: 35324914)
1. Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma.
Williams G; Llewelyn A; Thatcher R; Hardisty KM; Loddo M
PLoS One; 2022; 17(3):e0245817. PubMed ID: 35324914
[TBL] [Abstract][Full Text] [Related]
2. Utilisation of semiconductor sequencing for detection of actionable fusions in solid tumours.
Loddo M; Hardisty KM; Llewelyn A; Haddow T; Thatcher R; Williams G
PLoS One; 2022; 17(8):e0246778. PubMed ID: 35984852
[TBL] [Abstract][Full Text] [Related]
3. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
5. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
[TBL] [Abstract][Full Text] [Related]
6. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.
Ong M; Carreira S; Goodall J; Mateo J; Figueiredo I; Rodrigues DN; Perkins G; Seed G; Yap TA; Attard G; de Bono JS
Br J Cancer; 2014 Aug; 111(5):828-36. PubMed ID: 24983367
[TBL] [Abstract][Full Text] [Related]
7. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
8. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
9. Top advances of the year: Precision oncology.
Desai A; Reddy NK; Subbiah V
Cancer; 2023 Jun; 129(11):1634-1642. PubMed ID: 36946766
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
[TBL] [Abstract][Full Text] [Related]
12. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
13. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
[TBL] [Abstract][Full Text] [Related]
15. Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?
Rodler S; Jung A; Greif PA; Rühlmann K; Apfelbeck M; Tamalunas A; Kretschmer A; Schulz GB; Szabados B; Stief C; Heinemann V; Westphalen CB; Casuscelli J
Eur J Cancer; 2021 Mar; 146():1-10. PubMed ID: 33535139
[TBL] [Abstract][Full Text] [Related]
16. Identification of putative actionable alterations in clinically relevant genes in breast cancer.
Kaur P; Porras TB; Colombo A; Ring A; Lu J; Kang I; Lang JE
Br J Cancer; 2021 Oct; 125(9):1270-1284. PubMed ID: 34455425
[TBL] [Abstract][Full Text] [Related]
17. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
20. Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma.
Li JH; He ZQ; Lin FH; Chen ZH; Yang SY; Duan H; Jiang XB; Al-Nahari F; Zhang XH; Wang JH; Zhang GH; Zhang ZF; Li C; Mou YG
Mol Cell Probes; 2019 Aug; 46():101411. PubMed ID: 31173881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]